The Investing Club holds its 'Morning Meeting' every weekday at 10:20 a.m. ET.
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Tuesday's key moments. U.S. stocks were mixed on Tuesday. The Nasdaq Composite advanced 0.2%, outperforming the S & P 500's 0.1% gain and Dow Jones Industrial Average 's slight loss. "That's really been the theme that we saw yesterday throughout the year ...
MoffettNathanson reiterated its buy rating on Walt Disney stock, citing a return to growth for the company's studio division. Analysts pointed to the commercial success of Inside Out 2, which recently became the fastest animated movie to garner $1 billion at the box office. The analysts lowered their price target slightly to $125 from $120 apiece. The Club added to its Disney position on Monday due to the company's now-attractive valuation.
Apple Inc Microsoft Corp Novo Nordisk A/S Novo Nordisk A/S Eli Lilly And Co Dow Jones Industrial Average S&P 500 Index NASDAQ Composite Breaking News: Markets Markets Investment Strategy Jim Cramer Morning Meeting Recaps Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Alphabet names Eli Lilly veteran Ashkenazi as CFOAlphabet names Eli Lilly veteran Ashkenazi as CFO
Read more »
Alphabet taps Eli Lilly's Anat Ashkenazi as new CFOThe new Google executive will replace Ruth Porat, who will become president and chief investment officer of the company after nearly a decade as CFO.
Read more »
FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA advisors recommend Eli Lilly Alzheimer’s drug that slows diseaseEli Lilly's new Alzheimer's drug, donanemab, received approval from an advisory panel for the FDA. The full agency is expected to approve the drug by spring.
Read more »